INTRODUCTION
Uncovering in vivo functions served by different neuron classes is of clinical and fundamental interest. Tools enabling such functional mapping are in need and under development in various forms (Nakashiba et al., 2008; Yamamoto et al., 2003; Yu et al., 2004; and reviewed in Dymecki and Kim, 2007; Luo et al., 2008) . Here, we present RC::PFtox ( Figures 1A-1C and S1A-S1C), a broadly applicable genetic tool for silencing virtually any neuron subtype in the living mouse. Maximized in RC::PFtox is the attainable cell-type specificity of neuronal silencing, thus sharpened is the attainable link between neuron type and function served. Also offered is breadth in applicability across most neuron types.
RC::PFtox, a knockin allele of the ROSA26 (R26) locus (Zambrowicz et al., 1997), exploits the powerful and highly selective dual-recombinase methodology of intersectional gene activation (Awatramani et al., 2003; Farago et al., 2006; Jensen et al., 2008) (Figures 1A-1C and S1A-S1C) for conditional expression of a GFPtox fusion protein (Yamamoto et al., 2003) . Tox suppresses vesicle-mediated neurotransmitter release by cleaving the synaptic-vesicle-associated membrane protein VAMP2/synaptobrevin2 (Schiavo et al., 2000) . In the absence of VAMP2, assembly of the SNARE protein complex, needed for exocytic fusion of synaptic vesicles with plasmalemma, is inhibited (Schiavo et al., 2000) . Tox is quite potent, requiring fewer than ten molecules intracellularly to block 50% of synaptic vesicle exocytosis in Aplysia neurons (Schiavo et al., 2000) . Expression of GFPtox from RC::PFtox requires removal of two stop cassettes, a loxP-flanked cassette excisable by Cre recombinase and an FRT-flanked cassette, by Flpe ( Figures 1A-1C ). GFPtox action, therefore, should restrict to just those cells having expressed both Cre and Flpe recombinase. Requiring two recombination events allows for defining the targeted cell subtype with great specificity (cartooned in Figures S1A and S1B), that is, by pairwise combinations of expressed genes, rather than solely by a single-gene profile afforded by singlerecombinase or conventional transgenic strategies. Thus, confounding interference from silencing too heterogeneous a cell population is minimized, resulting in an improved capacity for delineating which neuron subtypes underlie specific behaviors or physiological processes. To maximize the scope of neuron subtypes amenable to silencing by RC::PFtox, and thus the breadth of applicability, we exploited a set of broadly active enhancer sequences-from R26 (Zambrowicz et al., 1997) and CAG (Niwa et al., 1991) -that, when coupled with the potency of tox, would be expected to equip RC::PFtox with the ability to suppress vesicular neurotransmission in a wide range of neuron subtypes (Farago et al., 2006; Muzumdar et al., 2007; Zong et al., 2005) . Thus, RC::PFtox can leverage immediately the extensive panel of existing recombinase mouse lines by endowing them with the new capacity to tease out neuron function upon partnering with RC::PFtox.
We validated this RC::PFtox method of neuronal silencing by demonstrating, through a range of assays, effective and selective inhibition of the granule-to-Purkinje cell synapse in vivo. Breadth of applicability of RC::PFtox was established through partnering with different Cre and Flpe recombinase drivers to target GFPtox delivery, in separate experiments, to disparate neuron subtypes. Among the different populations tested, were drivers capable of efficiently activating GFPtox expression in near all serotonergic neurons or in just a combinatorially defined subset. Parcelation of a panel of serotonin (5HT) related behavioral phenotypes was suggested. These findings not only validate RC::PFtox and the utility of intersectional silencing, but also provide evidence that the neural substrates involved in contextual fear conditioning, sensorimotor gating, and certain anxiety-related behaviors may be separable based on genetic cell lineage, offering hope to the possibility for selective therapeutics.
RESULTS
Dual Recombinase Regulation of GFPtox Delivery in RC::PFtox Mice Testing RC::PFtox required first applying it to an already welldefined neural system as proof of concept, and one not essential for viability, so as to allow postnatal analyses. We therefore targeted a major cerebellar circuit for silencing by partnering RC::PFtox with both Math1-cre (Matei et al., 2005) and hßact::Flpe transgenes (Rodriguez et al., 2000) . In this test case, cell specificity was determined by the Math1-cre transgene, given that the b-actin (hßact) sequences driving Flpe act broadly and efficiently during embryogenesis, especially early in development resulting in an animal in which virtually all cells harbor the target allele in a Flpe-recombined form (Rodriguez et al., 2000) . Although the high cell-type selectivity offered by the combinatorial platform of RC::PFtox was not fully exploited in this one example, given this breadth of Flpe recombination, this genotype allowed us to assess not only the dependency of GFPtox expression on Cre and Flpe events but also the efficacy of the remaining loxP-flanked stop cassette in preventing GFPtox transcription in cells having undergone only Flpe-mediated recombination-a feature critical for restricting GFPtox expression to only cells having undergone both Flpe-and Crerecombinations.
Stop cassette function indeed proved adequate. Only tripletransgenic Math1-cre, hßact::Flpe, RC::PFtox animals expressed GFPtox (Figure 1) , and only in neurons in which b-actin and Math1 enhancer elements were active at some point in their history, such as in mossy fiber precerebellar neurons, cerebellar granule cells, and neurons of the cerebellar nuclei ( Figures 1I-1K ). Recombination and consequent GFPtox delivery to Math1-credescendants was robust and highly efficient and specific, as evidenced by GFPtox detection (brown staining) in (1) the pontine gray nuclei ( Figure 1I versus control panel 1E), (2) the cerebellar granule cell layer (GCL) and the molecular layer (ML) which harbors the GFPtox-containing granule cell axons called parallel fibers (PFs), respectively ( Figure 1J versus control panel 1F)-note that Purkinje cells are devoid of GFPtox as expected given their lack of Math1 enhancer activity (Farago et al., 2006; Matei et al., 2005; Wang et al., 2005) -and (3) certain large output neurons in cerebellar nuclei ( Figure 1K versus control 1G). Furthermore, control double-transgenic hßact::Flpe, RC::PFtox siblings showed no GFPtox expression, indicating that the remaining loxP-flanked stop cassette was sufficiently robust across cell types ( Figure S1E ). Animals of the other possible Figure 1H) ; again, no GFPtox expression was detected, indicating that the remaining FRT-flanked stop cassette ( Figure 1B) 2D , insets, and Figure S3 ). Moreover, we detected proteolytic cleavage fragments of VAMP2 only in protein lysates from triple transgenics but not control siblings (data not shown). Thus, the loss of VAMP2 immunoreactivity observed in tripletransgenic animals likely resulted from GFPtox-mediated VAMP2 cleavage within granule cells. Loss of VAMP2 predicts a disruption in exocytic fusion of synaptic vesicles, leading to impaired synaptic transmission. We tested this by determining the properties of the PF-to-PC synapse in acute brain slices. Stimulation of PFs with a 100 Hz train ( Figure 2E ) evoked facilitating excitatory postsynaptic currents (EPSCs) in PCs ( Figure 2F ). By contrast, in triple transgenics, the same stimulus evoked little detectable response in PCs ( Figure 2G ). On average the synaptic responses were reduced more than 10-fold (in control and triple transgenics the averages were 324 pA and 22 pA and the medians were 118 pA and 3pA, respectively, n = 11 each, p = 0.0013 MannWhitney-Wilcoxon test [MWW] ). In slices from triple transgenics it was sometimes possible to evoke EPSCs following PF activation, but extremely high stimulus intensities were required (Figure S2 ). The decrease in EPSC amplitude did not result from an inability to stimulate PFs in the triple transgenics because the evoked presynaptic volleys produced by propagating action potentials in PFs had similar properties in triple transgenics and littermate controls ( Figures S2B and S2C ). Next, we assessed the selectivity of synapse suppression. Climbing fibers (CFs) from neurons in the inferior olive also synapse onto PCs; in triple transgenics, however, CFs should be GFPtox-negative and unaffected. Indeed, we found that CF-to-PC EPSCs in both control and triple-transgenic animals were similar in amplitude ( Figures 2H-2J ) (averages were 2.2 nA in control [n = 7] versus 2.4 nA in triple-transgenic animals [n = 10], p = 0.31 MWW test) and exhibited short-term depression that is characteristic of this synapse (paired-pulse ratio = 0.29 in control and 0.27 in triple transgenics) (Konnerth et al., 1990) . Collectively, these findings indicate a selective defect in neurotransmission between PFs and PCs. This defect is the result of granule cell dysfunction: (1) GFPtox-mediated depression of PF neurotransmitter release and (2) perhaps blockade of the mossy fiberto-granule cell synapse (an upstream synapse), given that mossy fiber neurons are also Math1-cre-descendants and positive for GFPtox.
Consistent with these electrophysiological deficits and the known roles played by the various Math1-descendant neuron populations, we observed in triple-transgenic Math1-cre, hßact::Flpe, RC::PFtox animals, robust and reproducible defects in gait, general motor coordination and balance ( Figures 2M, 2N , and Supplemental Movies). Also predicted is an accumulation of unreleased synaptic vesicles in PFs from triple transgenics (Schiavo et al., 2000) ; indeed, this was the case ( Figure 2K versus 2L). Thus, in triple-transgenic Math1-cre, hßact::Flpe, RC::PFtox animals, PF neurotransmission appeared disrupted as judged by molecular, electrophysiological, and ultrastructural criteria.
Validation of RC::PFtox across Different Neuron Types
Next, we partnered RC::PFtox with various other Cre and Flpe drivers to further sample its utility across different neuron types. For example, selective GFPtox expression in cerebellar PCs resulted in tremor upon movement and abnormal locomotion, while perinatal lethality resulted from broad GFPtox expression either throughout the midbrain and cerebellum or throughout the entire nervous system (summarized in Table S1 ). In addition to these expected phenotypes, silencing serotonergic neurons also proved informative. Selective expression of GFPtox in central serotonergic neurons (Pet1-descendant neurons [Hendricks et al., 1999] ) was efficiently and reproducibly achieved in triple transgenic ePet1::Flpe (Jensen et al., 2008) , hßact-cre, RC::PFtox animals, with excellent concordance between GFPtox and 5HT immunodetection . Furthermore, immunocytochemical analyses revealed that the serotonin (5HT)-positive axon varicosities, typical of serotonergic neurons (Maley and Elde, 1982) , were enlarged in triple transgenics as compared to controls ( Figure 3H versus 3D, 5HT immunodetection), suggesting a tox-dependent build-up of 5HT-loaded vesicles and diminished neurotransmitter release. Both kinds of varicosities (Agnati et al., 2006) were likely affected: those at the axon terminal involved in synaptic vesicular neurotransmission, as well as those along the axon length involved in vesicle-mediated volume transmission because enlarged varicosities were observed both at target regions as well as throughout axon tracts. Given the diffuse nature of serotonin projections and the heterogeneity of input to the postsynaptic target neurons, our phenotyping focused on behavioral output rather than additional histological analyses or electrophysiological recordings. We found that triple transgenic animals (n = 32) as compared to littermate controls (n = 34) were more exploratory and less averse to open, brightly lit spaces, suggestive of a lowering of anxiety-associated behaviors ( Figure 3I , p < 0.05). Triple-transgenic females (n = 16), especially, showed an anxiolytic response as compared to female controls (n = 17), not only in the open field test but also in the zero-maze and lightdark tests (F(1, 62) = 3.95, p < 0.05 and F(1,62) = 4.11, p < 0.05, respectively; data not shown). Additionally, triple transgenics
Neuron
Intersectional Neuronal Silencing (n = 32) showed enhanced conditioned freezing to contexts ( Figure 3J , p = .044), suggestive of enhanced associative learning, and showed enhanced prepulse-mediated inhibition of the acoustic startle reflex, indicative of enhanced sensorimotor gating ( Figure 3K , p = .007).
Intersectional Silencing Parcels Serotonin-Modulated Behaviors Next, we used RC::PFtox to selectively deliver GFPtox to a subset of serotonergic neurons rather than to the entire 5HT system. In particular, we targeted the subset of Pet1-descendant 5HT neurons that arise from serotonergic progenitors in rhombomere (r) 1; in other words, those 5HT neurons that have a history of both Pet1 and En1 expression (Jensen et al., 2008) . Consistent with our previously generated intersectional fate maps (Jensen et al., 2008) , we observed, in triple-transgenic En1-cre, ePet1::Flpe, RC::PFtox mice, GFPtox expression selectively in 5HT neurons of the dorsal raphe nucleus (DRN) in its entirety (B4, B6, and B7 nuclei using the Dahlstroem and Fuxe B1-B9
nomenclature [Dahlstroem and Fuxe, 1964] ) along with certain 5HT neurons considered classically to be part of the median raphe nucleus (MRN, also referred to as the B5, B8, and B9 nuclei) ( Figures 4E, 4F , and S4). Thus, using RC::PFtox, we were able to efficiently and reproducibly mark with GFPtox the full contingent of r1-(En1-) derived 5HT neurons. Consistent with this GFPtox expression pattern, we observed enlarged 5HT varicosities associated with rostral projections ( Figure 4H) serotonergic fibers (non-r1-derived and thus GFPtox-negative in this experiment) showed varicosity sizes similar to littermate controls ( Figure 4H inset, versus 4D and 4D inset). Phenotyping revealed behaviors consistent with lowered anxiety levels in triple-transgenic En1-cre, ePet1::Flpe, RC::PFtox mice (n = 20) as compared to littermate controls (n = 21) ( Figure 4I ). However, no behavioral differences were observed between triple-transgenic En1-cre, ePet1::Flpe, RC::PFtox and control mice with respect to contextual fear conditioning and prepulsemediated inhibition of the acoustic startle reflex (Figures 4J and  4K) . Thus, of the three behavioral phenotypes revealed upon expressing GFPtox in all Pet1-descendant 5HT neurons (Figure 3) , only the anxiety-related abnormalities were evoked upon silencing the r1-derived subset ( Figure 4I ). (1)
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DISCUSSION
Altering the synaptic activity of select, genetically defined neuron subsets in an otherwise undisturbed mouse offers powerful means for delineating neuron functions. Here, we describe the generation and validation of RC::PFtox mice that allow for the delivery of GFPtox, an inhibitor of synaptic vesicle exocytosis, to highly select neuron subtypes, while also being applicable across numerous, if not all, neuron subtypes. Activation of GFPtox expression was observed to be efficient and cell-type selective-consistent, in all cases, with the different Cre and Flpe drivers partnered with RC::PFtox. Importantly, GFPtox appeared well able to suppress vesicular neurotransmitter release in vivo, as determined by multiple independent means. Upon applying RC::PFtox to Math1-cre-descendant neurons including granule cells and their PF fibers in vivo, we observed: (1) PF-specific cleavage and loss of VAMP2, the molecular target of tox action; (2) synaptic vesicle accumulation in PFs, diagnostic for inhibition of vesicle exocytosis; (3) a greater than 10-fold reduction in EPSCs in PCs following PF stimulation; (4) normal EPSCs in PCs following CF stimulation, indicating that the synaptic suppression was specific for the PF-PC synapse; and (5) dysfunctional gait and motor coordination consistent with disruption of cerebellar and precerebellar circuitry. Collectively, these findings provide strong support for the utility of RC::PFtox as a neuronal silencing tool. Further, our findings not only support but also extend the important studies of Yamamoto and colleagues (Yamamoto et al., 2003) in which they used a tetracycline inducible, less broadly applicable, system to deliver GFPtox to cerebellar granule cells (Yamamoto et al., 2003) . A milder phenotype was reported likely reflecting many attribute differences including level and duration of GFPtox expression via the RC::PFtox approach and the more extensive cell populations targeted (cerebellar and precerebellar) in this particular proofof-principle example. Importantly, RC::PFtox, as applied here to silence PF-to-PC synapses, offers now the ability to ascertain changes in Purkinje cells that follow selective blockade of just the PF input while maintaining intact all other input classes, such as from climbing fiber neurons, stellate cells, and basket cells. Indeed, many such exciting experiments are made possible.
Application of RC::PFtox to silence serotonergic neurons also proved informative, with the results both validating the utility and versatility of RC::PFtox and revealing of 5HT neuron functions as relates to genetic cell lineage. Expression of GFPtox in Pet1-descendant 5HT neurons resulted in mice that exhibited behaviors consistent with lowered anxiety levels, enhanced associative learning (enhanced conditioned freezing to contexts), and enhanced sensorimotor gating (as reflected in enhanced prepulse-mediated inhibition of the acoustic startle reflex). Validating these findings, and thus RC::PFtox, are reports of phenotypes reciprocal to these for mice in which the extracellular level of 5HT is expected to be increased, as opposed to the expected decrease here: among examples, mice null for Slc6a4, the gene encoding the serotonin reuptake transporter, show elevated levels of anxiety-like behavior (Bengel et al., 1998; Holmes et al., 2003) ; mice treated perinatally with a selective serotonin reuptake inhibitor (an SSRI) show elevated levels of anxiety-like behavior in adulthood (Ansorge et al., 2004) ; and mice given MDMA (3,4 methylenedioxymethamphetamine; Ecstasy), a serotonin releaser, show diminished prepulse inhibition (Dulawa and Geyer, 1996) .
Interestingly, triple-transgenic ePet1::Flpe, hßact-cre, RC::PFtox animals are most similar to mice null for the 5HT receptor 1B with respect to anxiety, exploratory behavior, startle reactivity, and sensorimotor gating (Dulawa et al., 1997; Malleret et al., 1999; Saudou et al., 1994; Zhuang et al., 1999) . This commonality opens an avenue for thinking about behaviors that might be differentially served by 5HT1B receptors depending upon whether they are acting as heteroreceptors or autoreceptors-functions that have otherwise been challenging to delineate. The 5HT1B receptor localizes to axon terminals and upon activation inhibits neurotransmitter release; it acts either as an autoreceptor to limit 5HT release when expressed on serotonergic neurons or as a heteroreceptor to limit release of other neurotransmitters when expressed on nonserotonergic neurons (Maroteaux et al., 1992; Moret and Briley, 2000) . Triple-transgenic ePet1::Flpe, hßact-cre, RC::PFtox animals likely have diminished extracellular 5HT; those behaviors characterizing 5HT1B null mice that are shared with the triple transgenics are likely the result of functionally similar conditions. Loss of 5HT1B heteroreceptor function renders heterologous neurons deaf to 5HT, a situation functionally similar to loss of extracellular 5HT in triple transgenics; by contrast, loss of 5HT1B autoreceptor function would be expected to result in excessive extracellular 5HT. Thus, our data and the degree of phenocopy with 5HT1B null animals supports a larger heteroreceptor rather than autoreceptor role for the 5HT1B receptor in anxiety, exploratory behavior, and sensorimotor gating.
Of the phenotypes observed on silencing all Pet1-descendant 5HT neurons (reduced anxiety, enhanced conditioned freezing to contexts, and enhanced prepulse inhibition), only a reduction in anxiety-like behaviors was evoked upon silencing intersectionally the r1 (En1)-derived 5HT neuron subset. As we established previously (Jensen et al., 2008) , and confirmed here by GFPtox expression, r1 (En1)-derived 5HT neurons account for all DRN 5HT neurons (also referred to as the B4, B6, B7 clusters) and an intermingled subset of MRN 5HT neurons (intermingled within the B5, B8, B9 clusters). The MRN also receives contributions from two other progenitor pools-the 5HT progenitors that situate in r2 and those in r3 (Jensen et al., 2008) . Thus, it appears that contextual fear conditioning and prepulse inhibition map away from the r1 (En1)-derived subset of serotonergic neurons, and, by subtraction, map onto the r2-and/or r3-derived 5HT neuron subsets in the MRN. Note that these behaviors are not thought to be modulated by the more caudal 5HT neurons of the medulla (the B1-B3 classes).
Nongenetic approaches, such as focal lesioning of 5HT neuron subsets by pharmacological means (injection of 5,7-dihydroxytryptamine, a neurotoxin preferentially, although not exclusively, taken up by 5HT neurons) have resulted in varied and often conflicting findings as to the relative importance of MRN (Avanzi et al., 1998; Kusljic et al., 2003; Melik et al., 2000) versus DRN (Maier et al., 1993; Maier et al., 1995; Sipes and Geyer, 1995) 5HT neurons in modulating contextual fear conditioning and prepulse inhibition. Our genetic findings support the MRN model, and in particular, the likely importance of the r2-and/or r3-derived MRN neuron subtypes. It now becomes possible to test this hypothesis further through partnering RC::PFtox and ePet1::Flpe with various rhombomere specific Cre drivers (Jensen et al., 2008) . In this way it should be possible to better resolve different brain structures-different genetically defined 5HT neuron subsets-involved in specific 5HT modulated behaviors. Indeed, these initial intersectional findings are exciting because they support the notion that the neural substrates associated with these different behaviors may be separable, at least in part, by differences in genetic cell lineage (5HT populations defined by differences in developmental gene expression histories). These molecular differences, along with association with functional differences, suggest that selective therapeutics might one day become a possibility. This is of intense interest given that fear-conditioned learning is relevant to phobia, panic, and posttraumatic stress disorders (Garakani et al., 2006) , that altered sensorimotor gating is likely affected in disorders such as schizophrenia, obsessive compulsive disorder, Tourette's syndrome, and Huntington's disease (Braff et al., 2001) , and given the prevalence of and considerable impairment associated with generalized anxiety disorder, including comorbidity with clinical depression. Now that tool efficacy has been established, it will be important to map other 5HT-modulated behaviors onto these different genetically defined subsets of 5HT neurons. One especially intriguing example is offspring nurturing, which recently has been shown to be dependent upon the level of serotonergic neuron function (Lerch-Haner et al., 2008) .
In summary, RC::PFtox is a broadly applicable tool for silencing highly selective, molecularly defined neuron populations in vivo. By endowing the hundreds of already existing recombinase mouse lines with the capacity to uncover neuron functions in vivo it is a powerful resource. Moreover, the capability to select cells for silencing based on a combinatorial gene expression signature has multiple advantages: (1) highly selective cell subtypes can be manipulated, sharpening the capacity for mapping behaviors and/or physiological processes to specific neuron subtypes; (2) the generated ''neuron-tobehavior'' map, having an associated molecular signature, may prove informative with respect to relating gene functions to the uncovered cellular functions; and (3) it offers added temporal resolution in two ways. First, the two recombinase driver genes do not have to coincide temporally, rather they may be expressed at different times in a cell' s developmental history with activation of GFPtox triggered only after the second recombination event has been completed. Second, inducible forms of Cre or Flpe can be employed, such as CreER T2 or FlpeER T2 (Dymecki and Kim, 2007) , making it possible to silence cells at later points within the profile of a dynamically expressed driver gene. For example, using a Slc6a4:: CreER T2 (Gong et al., 2007 ) driver, we see induced postnatal recombination in virtually all 5-HTstaining neurons (R.D. Brust and S.M.D., unpublished data). While RC::PFtox offers molecular, spatial, and temporal control over GFPtox delivery in vivo, it does not, in its current form, offer reversibility of silencing-such enablement is the next step having established here the general efficacy and utility of the RC::PFtox approach across many neuron types. While the intersectional aspect of RC::PFtox is an important advantage, some experiments nonetheless may warrant GFPtox delivery following a single recombination event. RC::PFtox readily offers this feature as well through the ready derivation of two additional mouse lines: one that requires only Cre recombination to activate expression of GFPtox-we refer to this derivative allele as RC::Ptox, because the loxP cassette remains while the FRT cassette has been removed by germline deletion; and one that requires only Flpe recombination to activate GFPtox expression-we refer to this derivative allele as RC::Ftox, because the FRT cassette remains following germline removal of the loxP cassette. These three tools-RC::PFtox, RC::Ptox, RC::Ftox-coupled with the present and ever growing number of Cre and Flpe expressing mouse strains has considerable potential for advancing studies of neuron function, fate, and behavioral output.
EXPERIMENTAL PROCEDURES

DNA Constructs
Annealed oligonucleotides containing multiple cloning sites (SnaBI, AsiSI, SrtI, BbvCI, and AvrII) and flanked by FRT sites were subcloned into the complementary AgeI site of pBig-T (Srinivas et al., 2001 ) to generate our pPF vector. His3-SV40pA STOP sequences were amplified by PCR from pBS302 (Sauer, 1993) and subcloned into the AvrII site of pPF to generate pPF-His3-SV40pA. Mouse codon-optimized cDNA encoding tox was PCR amplified from pUAST (gift from Dr. Sean Sweeney) and ligated with cDNA encoding EGFP (ClonTech). The resulting GFPtox fragment was subcloned into the SacII and NotI site of pPFII-His3-SV40pA. The resulting vector was refered as pPFIIHis3-SV40pA-GFPtox. cDNA encoding mCherry was subcloned into the AsiSI site of pPFII-His3-SV40pA-GFPtox by blunt end ligation. The resulting vector was designated pPFII-Cherry-His3-SV40pA-GFPtox. The DNA region containing two stop cassettes and GFPtox was excised from pPFII-Cherry-His3-SV40pA-GFPtox using PacI and AscI sites and subcloned into the AsiSI and AscI sites of a CAG-MCS vector. The resulting vector was designated CAG-PFII-Cherry-His3-SV40pA-GFPtox. The fragment containing the CAG sequences, two stop cassettes, and GFPtox was excised using PacI and AscI and subcloned into the AscI and PacI site of pRosa26-1 (gift from Dr. Philippe Soriano) to generate pR26-CAG-PF-Cherry-GFPtox.
Generation, Breeding, and Genotyping of RC::PFtox Mice Linearized pR26-CAG-PF-Cherry-GFPtox (20 mg) was electrophorated into Tc-1 P5 ES cell (1-2 3 10 7 cells). ES cells were cultured and subjected to G418 selection. Mouse embryonic fibroblasts (cat # PMEF-N) and LIF ESGRO were purchased from Chemicon. Genomic DNA was isolated from 48 G418-resistant ES cell clones and analyzed by Southern. Fourteen clones were identified as homologous recombinants, and one was used in blastocyst injections to generate chimeric mice, with approval of the HMA Standing Committee on Animals. Triple-transgenic mice expressing GFPtox in specific types of neurons were obtained by combining RC::PFtox alleles with various Cre and Flpe transgenes including Math1-cre (Matei et al., 2005) , En1-cre (the cre knockin allele, En1 Cki ) (Kimmel et al., 2000; Zervas et al., 2004) , L7::cre (Barski et al., 2000) , hßact::Flpe (Rodriguez et al., 2000) , and ePet1::Flpe (Jensen et al., 2008) transgenes. Transmission of cre, Flpe, and RC::PFtox allele was assessed by PCR-based genotyping using the following primers.
Cre forward: 5 0 -GGCATGGTGCAAGTTGAATAACC-3 
Behavioral Analysis Breeding Scheme and Genetic Backgrounds
Triple-transgenic animals and control litter mates used in behavioral analysis were generated by crossing female Cre mice having FVB/N genetic background (hbact-cre) or C57B6 genetic background (En1-cre) with doubletransgenic male mice (ePet1::Flpe, RC::PFtox) having mixed genetic backgrounds of C57BL/6 and 129/SV. In all experiments, the pool of control animals was comprised of littermates to the experimental triple transgenics and were of either single-transgenic (cre, Flpe, or RC::PFtox) , double-transgenic (any of the possible combinations), or nontransgenic genotypes.
Fixed Bar Test
Test was done as previously described (Kadotani et al., 1996) . Mice were place on wood bar (5 3 5 mm width, 70 cm in length, 40 cm above ground) and measured time that the animal spends on the bar. Each mouse was tested three times, and maximum 60 s were allowed for each session. Elevated Zero-Maze Animals were brought into the darkened testing area a minimum of 30 min before testing and allowed to acclimate. Mazes were dimly illuminated by 15 W red bulbs suspended above the maze. To begin the test, animals were placed into a closed quadrant of the maze. The test session was 5 min in duration.
Once an animal had been tested, it was placed in a holding cage until all animals from the home cage had been tested.
Open Field
Animals were brought into testing area a minimum of 30 min (but ideally 45 min to 1 hr) before testing. Animals were allowed to acclimate to area. Open field session was 20 min in length. To begin the test, individual animals were removed from the cages and placed into the center of an open field monitor.
Light/Dark
Animals were acclimated to the darkened room for a minimum of 30 min. A lamp with 15 W bulb was located directly above the light portion of the light/ dark box. To begin the 10 min test, animals were placed in the light half of the box. The guillotine door was then removed to allow animals to freely move between the two halves of the box. The amount of time spent in the light versus dark compartment was measured. Once an animal had been tested, it was placed in a holding cage until all animals from the home cage had been tested. Acoustic Startle/Prepulse Inhibition Animals were placed in the startle chamber with a 65 db background white noise and allowed to habituate. Over an approximately 15 min session, 55 db pseudorandom trials were given. A 120 db white noise burst was used as the acoustic startle stimulus. Prepulses were 70, 80, and 85 db white noise bursts which preceded the startle stimulus by 10 ms. Startle response to the startle stimulus and to each of the prepulse db levels was measured.
Fear Conditioning
The first part of fear conditioning (Training) was carried out approximately 1.5 to 2 hr after the startle and prepulse inhibition test. Animals were placed in the fear conditioning chambers and allowed to habituate for 2.5 min. Animals were then presented with three pairings of an 85 db tone and 0.36 mA foot shock. The tone was 30 s in duration and the shock was presented during the last 2 s of the tone. There was a 2.5 min interval between each of the tone + shock pairings. On the day following the training session, animals were placed back into the same chambers where they underwent training. During this 6 min session, activity (beam breaks) per 30 s bin was measured and compared to activity during the habituation period on the training day. This procedure was used as a measure of conditioning to the context. Approximately 2 hr later, the behavior of the mice was tested in an altered context. The fear conditioning chambers were altered by placing a gray, square tile over the grid floor, placing a black Plexiglas insert over walls of the chambers, and attaching a small cup containing orange oil diluted in water in the upper corner of the box. Animals are allowed to explore the altered environment for 2.5 min, after which time, the conditioned stimulus (tone) was presented for 2.5 min. Activity (beam breaks) was evaluated in 30 s bins. This procedure was used as a measure of conditioning to the auditory cue. All animals were tested in the elevated zero-maze, open field, light/dark, acoustic startle/prepulse inhibition, and fear conditioning tasks. On the first day of testing animals were tested in the elevated zero-maze. Starting the following day, and over a 4 day period animals were tested in the remaining tasks in the aforementioned order as described elsewhere (Cook et al., 2007) .
Statistical Analyses
All data were first analyzed using a two variable (genotype, sex) between subjects Analysis of Variance (ANOVA). Where significant results were obtained, post-hoc comparisons were performed using Tukey's Least significant difference (LSD) test. A p value of p < 0.05 was considered to be significant statistically.
Histochemistry and Microscopy
Animals were transcardially perfused with 0.1 M phosphate-buffered saline (PBS) (pH 7.4) followed by 4% paraformaldehyde in 0.1 M PBS. Brains were harvested from the perfused animals, immersion-fixed in 4% paraformaldehyde in 0.1 M PBS at 4 C 12 hr, and cryoprotected in 30% sucrose/PBS for 48 hr. 40 mm frozen sections were sliced using a cryostat, collected to PBS, and processed as free-floating sections for immunohistochemistry experiments using the Vectastain ABC Elite peroxidase rabbit IgG kit (Vector, USA, PK6101) for DAB/peroxidase-mediated antigen detection. For fluorescent immunohistochemistry, Cy2, Alexa 488, Cy3, or Cy5-conjugated secondary antibody was used for detecting primary antibody. Imaging of the fluorescent samples was performed on a Leica SP2 inverted confocal microscope using excitation with a 488 nm laser for Cy2 and Alexa 488 fluorophore, a 594 nm laser for Cy3, and a 633 nm laser for Cy5.
Electron Microscopy
Animals were transcardially perfused with 0.1 M phosphate-buffered saline (PBS) (pH 7.4) followed by 2% paraformaldehyde/2% glutaraldehyde fixative. Brains were harvested from the perfused animals, immersion-fixed in 2% paraformaldehyde/2% glutaraldehyde fixative at 4 C for 12 hr. 100 mm sections were sliced using a vibrotome and collected to PBS. Samples were then washed several times in 0.1 M cacodylate buffer (pH 7.4) and osmicated in 1% osmium tetroxide/1.5% potassium ferrocyanide solution for 3 hr, followed by several washes with distilled water. 1% uranyl acetate in maleate buffer (pH 5.2) was added for one hour then washed several times with maleate buffer. This was followed by a graded cold ethanol series up to 100% which is changed three times over one hour. The samples were treated three times with propylene oxide over one hour, and then placed in 1:1 mixture of propylene oxide and plastic embedding resin including catalyst overnight. Samples were embedded in pure plastic the next day and put into 60 C oven for 1 or 2 days.
Sample blocks were cut for 95 nm sections with Leica ultracut microtome, picked up on 100 m formvar coated Cu grids, stained with 0.2% lead citrate, and imaged under the Philips Technai BioTwin Spirit Electron Microscope.
Electrophysiology
All procedures were approved by the Harvard Medical Area Standing Committee on Animals. Whole-cell voltage-clamp recordings were performed in Purkinje cells as previously described for parallel fiber (Dittman et al., 2000) and climbing fiber (Foster et al., 2002) synapses. Slices from P13-P14 tripletransgenic mice and age-matched littermate controls were maintained at 33 C-35 C. The extracellular ACSF contained: 125 mM NaCl, 26 mM NaHCO3, 25 mM glucose, 2.5 mM KCl, 1.25 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, and was bubbled with 95% O 2 /5% CO 2 . Glass electrodes (1-1.5 MU) were filled with an internal solution consisting of: 35 mM CsF, 100 mM CsCl, 10 mM EGTA, 10 mM HEPES. Bicuculline (20 mM) was added to the ACSF to block inhibitory currents. Parallel fiber EPSCs were recorded from Purkinje cells held at À60 mV in 275 mm-thick transverse cerebellar slices. Glass stimulating electrodes (0.7-1 MU) filled with ACSF were placed 250-300 mm from the cell body in the inner third of the molecular layer and care was taken to do this consistently across experiments. CGP55845A was added to the ACSF to block GABA B receptor activation. Climbing fiber EPSCs were recorded from Purkinje cells held at À30 mV in 250 mm-thick parasagittal slices. NBQX (300 nM) was included in the external solution to minimize series resistance errors and allow quantification of the otherwise prohibitively large climbing fiber EPSCs.
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